TOP - Daily
Blocking miR-21 overexpression was found to retrieve trastuzumab sensitivity in trastuzumab-resistant breast cancer cells, in a study of cell lines derived from HER2-postive breast carcinomas. This theory was derived from identification of overexpression of miR-21 in HER-positive, trastuzumab-resistant cells. The researchers also found that miR-21 upregulation in trastuzumab-resistant cells led to PTEN reduction.
Read More ›
For gastric cancer patients with severe peritoneal metastases, 5-fluorouracil (FU)-based chemotherapy regimens provided only marginal improvement in time to treatment failure (TTF) and overall survival (OS). In a retrospective analysis of 92 patients treated between 2001 and 2007, median TTF was 1.9 months, and median OS was 4.6 months. The researchers concluded that a combination of paclitaxel and 5-FU holds promise for this population, but that studies are needed to determine if sequential of combined therapy is better.
Read More ›
The US Food and Drug Administration (FDA) has approved sunitinib malate (Sutent, Pfizer) as the first anti–vascular endothelial growth factor (VEGF) therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (PNETs) in patients with unresectable, locally advanced, or metastatic disease.
Read More ›
WASHINGTON, DC—New biomarkers for urologic cancers should help clinicians not only diagnose prostate and bladder cancers but also help them distinguish between indolent and aggressive disease. Urologists and oncologists learned about 3 new biomarkers for prostate cancer at the 2011 annual meeting of the American Urological Association, held this week in Washington, DC.
Read More ›